Development of Apo Mimetic Peptides for the Treatment Cardiovascular Disease
$1,752,138ZIAFY2017HLNIH
National Heart, Lung, And Blood Institute
Investigators
Linked publications & trials
Paper 36337032Paper 34653581Paper 34097448Paper 33800446Paper 33442570Paper 32222278Paper 31996466Paper 30863636Paper 30397748Paper 30359697Paper 29440748Paper 29141139Paper 29100061Paper 28522696Paper 28242049Paper 27879324Paper 27814978Paper 27758769Paper 26613945Paper 25634835Paper 25395590Paper 25154602Paper 24813055Paper 23985823Paper 23874769Paper 23515282Paper 23505317Paper 23325471Paper 23118226Paper 23042953Paper 22508840Paper 22427535Paper 22408624Paper 21972383Paper 21798543Paper 21672528Paper 21266551Paper 21115733Paper 20508181Paper 20484557Paper 19965776
Abstract
In the past year we have filed several patents related to both ApoA-I and ApoC-II mimetic peptides. For 5A, an ApoA-I mimetic peptide, we have completed the pre-clinical toxicology studies and have produced GMP grade material and plan to file and IND in the coming year. For the apoC-II mimetic peptide, we developed a CRADA with Corvidia Inc and have developed several new apoC-II mimetic peptides and are optimizing its formulation for possible future drug development. We have recently started a study to systematically examine the structural features of apolipoproteins that preferentially direct their attachment to different types of lipoproteins.
View original record on NIH RePORTER →